Quick Answer
GeneDx Holdings Corp. reported Net Income Loss of -$21.02 million for the year ending 2025.
- GeneDx Holdings Corp. showed an increase of +59.8% in Net Income Loss from 2024 to 2025.
- This data is from GeneDx Holdings Corp.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$26.99 million | Q2 2020: -$32.05 million | Q3 2020: -$56.62 million | Q4 2020: -$125.68 million | Q1 2021: -$191.78 million | Q2 2021: -$46.16 million | Q3 2021: $32.73 million | Q4 2021: -$40.19 million | Q1 2022: -$76.90 million | Q2 2022: -$85.74 million | Q3 2022: -$77.58 million | Q1 2023: -$60.99 million | Q2 2023: -$46.72 million | Q3 2023: -$42.29 million | Q1 2024: -$20.24 million | Q2 2024: -$29.17 million | Q3 2024: -$8.31 million | Q1 2025: -$6.53 million | Q2 2025: $10.81 million | Q3 2025: -$7.64 million.
- Over the full 7 years of available data (2019 to 2025), GeneDx Holdings Corp.'s Net Income Loss has grown by 29.2%.
- Historical annual values: Fiscal year 2025: -$21.02 million | Fiscal year 2024: -$52.29 million | Fiscal year 2023: -$175.77 million | Fiscal year 2022: -$548.98 million | Fiscal year 2021: -$245.39 million | Fiscal year 2020: -$241.34 million | Fiscal year 2019: -$29.70 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: